ReviewWorld journal of gastroenterology2014
Helicobacter pylori: friend or foe?
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Guideline-based bismuth quadruple therapy for helicobacter pylori infection in China: A systematic review and network meta-analysis.PloS one · 2025Pooled it
- AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review.Gastroenterology · 2021Guideline
- Prognostic impact of deprivation on esophagogastroduodenoscopy outcome.Endoscopy international open · 2024Article
- Review
- A pilot study of non-invasive diagnostic tools to detect Helicobacter pylori infection and peptic ulcer disease.Scientific reports · 2023Article
- Global Trend on Machine Learning inGlobal health, epidemiology and genomics · 2023Article
- Gastric Cancer Due to ChronicDiseases (Basel, Switzerland) · 2022Review
- Traditional and Modern Diagnostic Approaches in Diagnosing PediatricChildren (Basel, Switzerland) · 2022Review
- Evolution of Diagnostic Methods forDiagnostics (Basel, Switzerland) · 2022Review
- Profiling of the Conjunctival Bacterial Microbiota Reveals the Feasibility of Utilizing a Microbiome-Based Machine Learning Model to Differentially Diagnose Microbial Keratitis and the Core Components of the Conjunctival Bacterial Interaction Network.Frontiers in cellular and infection microbiology · 2022Article
- In Vitro Antineoplastic and Antiviral Activity and In Vivo Toxicity ofMolecules (Basel, Switzerland) · 2021Article
- Helicobacter pylori infection causes both protective and deleterious effects in human health and disease.Genes and immunity · 2021Review
- Review
- The Gastric Mucosa from Patients Infected with CagA+ or VacA+ Helicobacter pylori Has a Lower Level of Dual Oxidase-2 Expression than Uninfected or Infected with CagA-/VacA- H. pylori.Digestive diseases and sciences · 2016Article
- Lipopolysaccharide modification in Gram-negative bacteria during chronic infection.FEMS microbiology reviews · 2016Review
- Metabolic Interaction of Helicobacter pylori Infection and Gut Microbiota.Microorganisms · 2016Review
- Fermented Foods: Are They Tasty Medicines for Helicobacter pylori Associated Peptic Ulcer and Gastric Cancer?Frontiers in microbiology · 2016Review
- Micronutrients: A Double-Edged Sword in Microbe-Induced Gastric Carcinogenesis.Trends in cancer · 2015Review
- Microbiology and ecology are vitally important to premedical curricula.Evolution, medicine, and public health · 2015Review
- Association between Virulence Factors and TRAF1/4-1BB/Bcl-xL Expression in Gastric Mucosa Infected with Helicobacter pylori.Gastroenterology research and practice · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Helicobacter pylori (H. pylori) is a Gram-negative spiral bacterium that is present in nearly half the world's population. It is the major cause of peptic ulcer disease and a recognized cause of gastric carcinoma. In addition, it is linked to non-ulcer dyspepsia, vitamin B12 deficiency, iron-deficient anemia and immune thrombocytopenic purpura. These conditions are indications for testing and treatment according to current guidelines. An additional indication according to the guidelines is "anyone with a fear of gastric cancer" which results in nearly every infected person being eligible for eradication treatment. There may be beneficial effects of H. pylori in humans, including protection from gastroesophageal reflux disease and esophageal adenocarcinoma. In addition, universal treatment will be extremely expensive (more than $32 billion in the United States), may expose the patients to adverse effects such as anaphylaxis and Clostridium difficile infection, as well as contributing to antibiotic resistance. There may also be an as yet uncertain effect on the fecal microbiome. There is a need for robust clinical data to assist in decision-making regarding treatment of H. pylori infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.